MX2022009315A - Tratamiento del carcinoma de la corteza suprarrenal con moduladores selectivos del receptor de glucocorticoides (sgrm) e inhibidores de los puntos de control de los anticuerpos. - Google Patents

Tratamiento del carcinoma de la corteza suprarrenal con moduladores selectivos del receptor de glucocorticoides (sgrm) e inhibidores de los puntos de control de los anticuerpos.

Info

Publication number
MX2022009315A
MX2022009315A MX2022009315A MX2022009315A MX2022009315A MX 2022009315 A MX2022009315 A MX 2022009315A MX 2022009315 A MX2022009315 A MX 2022009315A MX 2022009315 A MX2022009315 A MX 2022009315A MX 2022009315 A MX2022009315 A MX 2022009315A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
cell
grm
adrenocortical carcinoma
sgrms
Prior art date
Application number
MX2022009315A
Other languages
English (en)
Inventor
Andrew Greenstein
Stacie Shepherd
Andreas Grauer
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2022009315A publication Critical patent/MX2022009315A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer métodos y composiciones para el tratamiento de un sujeto que padece de carcinoma de la corteza suprarrenal y que tiene un exceso de cortisol. Los métodos proporcionan beneficios terapéuticos que incluyen la reducción de la carga tumoral del ACC, la restauración de las vías de señalización de las células T y de las células asesinas naturales (NK, por sus siglas en inglés), el aumento de la infiltración de las células T y de las células NK en el tumor de ACC, la reducción de la infiltración de los neutrófilos en el tumor de ACC en el paciente y otros beneficios terapéuticos. Los métodos incluyen la administración de un modulador del receptor de glucocorticoides (GRM, por sus siglas en inglés) (que puede ser un modulador selectivo del receptor de glucocorticoides (SGRM, por sus siglas en inglés)) y un inhibidor del punto de control de los anticuerpos. En algunas modalidades, el GRM (por ejemplo, un SGRM) se administra por la vía oral. El GRM puede ser un compuesto no esteroideo que comprende: una estructura de azadecalina fusionada; una estructura de azadecalina fusionada con heteroaril cetona; o una estructura de azadecalina fusionada con octahidro.
MX2022009315A 2020-01-29 2021-01-26 Tratamiento del carcinoma de la corteza suprarrenal con moduladores selectivos del receptor de glucocorticoides (sgrm) e inhibidores de los puntos de control de los anticuerpos. MX2022009315A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062967517P 2020-01-29 2020-01-29
US202063040941P 2020-06-18 2020-06-18
US202063125630P 2020-12-15 2020-12-15
PCT/US2021/015124 WO2021154750A1 (en) 2020-01-29 2021-01-26 TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS

Publications (1)

Publication Number Publication Date
MX2022009315A true MX2022009315A (es) 2022-08-22

Family

ID=77079925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009315A MX2022009315A (es) 2020-01-29 2021-01-26 Tratamiento del carcinoma de la corteza suprarrenal con moduladores selectivos del receptor de glucocorticoides (sgrm) e inhibidores de los puntos de control de los anticuerpos.

Country Status (13)

Country Link
US (1) US20230053364A1 (es)
EP (1) EP4096663A4 (es)
JP (1) JP2023516885A (es)
KR (1) KR20220133275A (es)
CN (1) CN115361952A (es)
AU (1) AU2021214938B2 (es)
BR (1) BR112022015011A2 (es)
CA (1) CA3165708A1 (es)
CL (1) CL2022002015A1 (es)
IL (1) IL294862A (es)
MX (1) MX2022009315A (es)
WO (1) WO2021154750A1 (es)
ZA (1) ZA202207893B (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4851345B2 (ja) * 2004-01-09 2012-01-11 コーセプト セラピューティクス， インコーポレイテッド アザデカリン糖質コルチコイド受容体モジュレーター
EP3423453A4 (en) * 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CONTROL POINT INHIBITORS

Also Published As

Publication number Publication date
ZA202207893B (en) 2023-12-20
CA3165708A1 (en) 2021-08-05
KR20220133275A (ko) 2022-10-04
WO2021154750A1 (en) 2021-08-05
JP2023516885A (ja) 2023-04-21
EP4096663A4 (en) 2023-10-25
AU2021214938A1 (en) 2022-09-08
IL294862A (en) 2022-09-01
BR112022015011A2 (pt) 2022-09-20
AU2021214938B2 (en) 2024-02-08
CL2022002015A1 (es) 2023-01-20
CN115361952A (zh) 2022-11-18
EP4096663A1 (en) 2022-12-07
US20230053364A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
Ji et al. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action
Nepal et al. Autophagy induction by leptin contributes to suppression of apoptosis in cancer cells and xenograft model: involvement of p53/FoxO3A axis
Yu et al. Bradykinin enhances cell migration in human prostate cancer cells through B2 receptor/PKCδ/c‐Src dependent signaling pathway
Filaretova The hypothalamic–pituitary–adrenocortical system: Hormonal brain–gut interaction and gastroprotection
Carpentier et al. Steroid‐sparing effects of angiotensin‐II inhibitors in glioblastoma patients
Zhang et al. Local anesthetic lidocaine and cancer: insight into tumor progression and recurrence
Uemura et al. Renin‐angiotensin system is an important factor in hormone refractory prostate cancer
Almutlaq et al. The effect of local renin angiotensin system in the common types of cancer
Huang et al. Osteoimmunology: The correlation between osteoclasts and the Th17/Treg balance in osteoporosis
Katsinelos et al. Aggressive treatment of acute anal fissure with 0.5% nifedipine ointment prevents its evolution to chronicity
Schwieger‐Briel et al. Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa
Hanks Opioid-responsive and opioid-non-responsive pain in cancer
Ma et al. Formalin irrigation for hemorrhagic chronic radiation proctitis
Xu et al. Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor‐α inhibited endothelial nitric oxide synthase expression in endothelial‐trophoblast cellular networks
Saager et al. Ramipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation
ZA202207893B (en) Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (sgrms) and antibody checkpoint inhibitors
Matsubara et al. Phase‐1 study of abiraterone acetate in chemotherapy‐naïve Japanese patients with castration‐resistant prostate cancer
Wang et al. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells
McGiff et al. Prostaglandins, kinins and the regulation of blood pressure
Filaretova et al. Gastroprotective action of glucocorticoid hormones during NSAID treatment
Rosenbach et al. Dermatologic therapeutics: thalidomide. A practical guide
Choi et al. Effect of 4‐chloro‐7‐trifluoromethyl‐10H‐benzo [4, 5] furo [3, 2‐b] indole‐1‐carboxylic acid on the intraurethral pressure in a rat model of benign prostatic hyperplasia
Ng et al. Omeprazole promotes gastric epithelial cell migration
RU2166947C1 (ru) Способ лечения распространенного рака предстательной железы
Kim et al. EP887 A synergistic anticancer effect of combination treatment with a cell cycle checkpoint kinase 1 inhibitor and PARP inhibitor in BRCA wild type epithelial ovarian cancer